HOME >> MEDICINE >> NEWS
People Who Are Diabetic And Glucose Intolerant Can Benefit From "Statin" Drug Therapy, Even If Cholesterol Levels Are Normal

DALLAS, Dec. 8 -- A cholesterol-lowering drug may help reduce the risk of another heart attack and the need for artery-opening procedures in people with diabetes and heart disease who have average blood levels of cholesterol, according to a study in today's issue of Circulation: Journal of the American Heart Association.

The study involved a subgroup of 586 diabetic individuals in the Cholesterol and Recurrent Events (CARE) trial, a five-year study that compared therapy using the drug pravastatin to placebo in men and women who had a previous heart attack and average blood levels of cholesterol.

"Although diabetes is a major risk factor for heart disease, little information is available on the effects of cholesterol-lowering therapies in individuals with diabetes," says co-author Frank M. Sacks, M.D., associate professor of medicine at Harvard Medical School and Brigham and Women's Hospital, Boston. Because the CARE trial population -- a total of 4,159 patients from 80 clinical centers in the United States and Canada -- included a large number of individuals, scientists had enough data to determine whether pravastatin therapy reduced the risk of recurrent heart attack or the need for treatment to unblock the arteries in people with diabetes.

Pravastatin is one of the statin class of cholesterol-lowering drugs called HMG CoA inhibitors.

Sacks reports that, compared with those in the placebo group, diabetic patients who received pravastatin had a 25 percent reduction in relative risk of having another heart attack. The relative risk of needing coronary artery bypass or angioplasty to unblock blood vessels was reduced by 32 percent in the statin-treated group.

The researchers also analyzed data from a subgroup of 342 people without diabetes who met the American Diabetes Association's definition of being glucose intolerant (fasting blood glucose levels between 110 to 125 mg/dL). "This subgroup had a higher rate of coronary events, such as recu
'"/>

Contact: Carole Bullock
caroleb@heart.org
214-706-1279
American Heart Association
7-Dec-1998


Page: 1 2

Related medicine news :

1. People wounded in tsunami at risk of undetected fungal infections
2. People on food stamps cant afford heart-healthy meals
3. People are of two minds on moral judgments
4. People with low incomes more likely to develop brain tumors
5. People are averse to taking drugs
6. People with chronic eye diseases not getting recommended eye exams
7. People with large pupils can now get LASIK and avoid night vision disturbances
8. People only slightly more likely to die after episodes of stagnant air
9. People with food allergies should not only be careful about what they eat
10. People who give, live longer: U-M study shows
11. People near freeways are exposed to 30 times the concentration of dangerous particles

Post Your Comments:
(Date:5/20/2013)... The Multiple System Atrophy Coalition (formerly ... its new Multiple System Atrophy (MSA) Research Grant ... MSA Coalition’s grass roots fundraising has grown and enabled ... support to now include education, advocacy and research funding ... by The Coalition go directly into a dedicated MSA ...
(Date:5/20/2013)... Gilman Law LLP, a leading pharmacy law and ... troubled by a new study that reveals that pancreatic ... diabetes drugs are growing. The analysis, conducted by ... 71 Byetta pancreatic cancer reports had been made to ... June 30, 2012. Overall, Byetta and other ...
(Date:5/20/2013)... Sporturf, an international manufacturer and builder of ... the Midwest with the opening of the company’s third ... Midwest is under the leadership of President Craig Shonk, ... , “This strategic move opens up a ... noted Shonk. “Bringing an ISO manufacturer and a Midwest-based ...
(Date:5/20/2013)... Plains, NY (PRWEB) May 20, 2013 ... firm of Levy Phillips & Konigsberg LLP ... Street in White Plains, New York. LPK will better ... in the Hudson Valley, including Westchester, Putnam, Rockland, Orange, ... helping families affected by asbestos-related diseases throughout New York, ...
(Date:5/20/2013)... VA (PRWEB) May 20, 2013 Orthopaedic ... successfully performed a procedure using SpineFrontier’s FacetFuse Screw System ... System. The operation took place on Tuesday, April ... Newport News, VA. The surgery was a facet ... year-old, female patient. , Dr. Carlson described the case, ...
Breaking Medicine News(10 mins):Health News:Multiple System Atrophy (MSA) Research Grant Program Announced 2Health News:Multiple System Atrophy (MSA) Research Grant Program Announced 3Health News:Multiple System Atrophy (MSA) Research Grant Program Announced 4Health News:Multiple System Atrophy (MSA) Research Grant Program Announced 5Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 2Health News:Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports 3Health News:Sporturf Expands into the Midwestern U.S. 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 2Health News:Westchester Mesothelioma Lawyers Open Office in White Plains, New York 3Health News:Dr. Jeffrey Carlson Successfully Performs Procedure Using SpineFrontier’s Less Exposure Surgery Technology: FacetFuse 2Health News:Dr. Jeffrey Carlson Successfully Performs Procedure Using SpineFrontier’s Less Exposure Surgery Technology: FacetFuse 3
(Date:5/20/2013)... 2013 Sequent Medical, Inc. announced today that ... Layer") family of WEB ® Aneurysm Embolization Devices, ... models in select neurovascular centers in Europe.  The SL ... will enable physicians to treat a broader range of ... configurations are made possible by further advancement of Sequent ...
(Date:5/20/2013)... ALISO VIEJO , Kalifornien, 20. Mai ... heute bekannt, dass das Unternehmen die CE-Kennzeichnung ... Implantate zur Embolisation von Aneurysmen erhalten hat. ... in Europa bereits mit der kontrollierten Einführung ... Profil bietet die SL-Produktfamilie auch ein verbessertes ...
(Date:5/20/2013)... , May 20, 2013   Life Technologies ... that its Applied Biosystems™ 3500 Dx and 3500xL Dx ... for Protection against Health Risks in Mexico ... major extension of Life Technologies, capabilities to serve the ... with Sanger -based solutions.  ...
Breaking Medicine Technology:Sequent Medical, Inc. Launches New SL Family of WEB Aneurysm Embolization Devices 2Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 2Sequent Medical, Inc. bringt neue SL-Produktfamilie seiner WEB Geräte zur Embolisation von Aneurysmen auf den Markt 3Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 2Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 3
Cached News: